Article
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Journal of hepatology - 1 Feb 2006
Ferenci Peter, Formann Elisabeth, Laferl Hermann, Gschwantler Michael, Hackl Franz, Brunner Harald, Hubmann Rainer, Datz Christian, Stauber Rudolf, Steindl-Munda Petra, Kessler Harald H, Klingler Anton, Gangl Alfred
Abstract excerpt
BACKGROUND/AIMS: Amantadine may augment virological response rates to interferon-based therapy in chronic hepatitis C patients. Using a novel design, amantadine was studied in naïve genotype 1 patients treated in combination with peginterferon alfa-2a (40KD)/ribavirin. METHODS: Patients enrolled in this randomized, placebo-controlled multicenter trial were stratified by single-dose interferon sensitivity (stratum...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.